The Economics of One

The first human genome cost approximately $2.7 billion and took 13 years to sequence. A clinical-grade whole genome sequence today costs $300 to $500 and takes days. The same cost collapse is happening in individualized drug development, and it changes what is possible for families whose children have mutations shared by no one else in any database.

Milasen, the antisense oligonucleotide designed for Mila Makovec's specific CLN7 Batten disease mutation, cost roughly $2 million to develop. That figure covered everything: target identification, ASO design, candidate screening in cell culture, toxicology studies in rats, GMP manufacturing, regulatory preparation, and FDA emergency IND submission. The timeline from mutation identification to first injection was approximately 10 months.

By comparison, Zolgensma, the gene therapy for spinal muscular atrophy developed through a traditional pharmaceutical pipeline, costs $2.1 million per dose and took more than a decade from concept to approval. The per-treatment costs are converging. The development timelines are not.

The convergence is the economic thesis for individualized medicine. If a bespoke drug for one person costs roughly the same as a mass-manufactured drug for thousands, the question of whether individualized therapy is "economically viable" has already been answered.

What Each Component Costs

The cost of an individualized ASO program breaks into discrete components, most of which have been declining independently.

Whole genome sequencing to identify the mutation: $300 to $500 for the sequencing itself, $3,000 to $5,000 when clinical-grade interpretation, genetic counseling, and reporting are included. This was $100 million in 2001. The cost reduction is six orders of magnitude in 24 years.

Target identification and ASO design: computational work to identify the RNA target, design candidate oligonucleotide sequences, and predict binding efficiency and off-target effects. This phase is measured in weeks and costs tens of thousands of dollars. Machine learning tools are accelerating the design step, reducing the number of candidate molecules that need to be synthesized and tested.

Candidate screening in cell models: the designed ASO candidates are tested in the affected person's own cells (typically fibroblasts or iPSC-derived cells) to confirm that they correct the splicing defect or restore protein production. This requires cell culture facilities and takes weeks. Cost: tens of thousands of dollars.

Oligonucleotide synthesis: the raw chemistry of manufacturing the ASO molecule. Clinical-grade oligonucleotide synthesis costs thousands of dollars for the quantities needed to treat one person. The molecules are small (typically 18 to 25 nucleotides), chemically modified for stability, and produced by solid-phase synthesis. Multiple contract manufacturers now offer this service, creating competitive pressure on pricing.

GMP manufacturing: the expensive step. Good Manufacturing Practice compliance requires documented processes, quality testing, sterility assurance, and facility certification. GMP manufacturing of a clinical-grade ASO batch costs hundreds of thousands of dollars. This is the component where the regulatory burden is highest and the cost reduction is slowest.

Toxicology studies: condensed toxicology packages for individualized ASOs, designed to establish a basic safety profile before first-in-human dosing, cost $100,000 to $300,000. Traditional toxicology packages for a new drug class cost millions and take years. The condensed approach is possible because the ASO chemistry class (2'-O-methoxyethyl modification, phosphorothioate backbone) has an established safety profile from approved drugs like nusinersen. Each new ASO within the same chemistry class carries less toxicological uncertainty than the first.

Regulatory preparation and IND submission: the documentation required for FDA review. For an individualized ASO under the Plausible Mechanism Framework, this is streamlined relative to a traditional IND. Cost: tens of thousands to low hundreds of thousands of dollars in specialized regulatory consulting.

Total estimated cost for an individualized ASO program today: $1 to $3 million per person, depending on the complexity of the mutation, the availability of cell models, the manufacturing requirements, and the regulatory pathway.

Where the Costs Are Falling

The components that depend on information technology (sequencing, target identification, ASO design, computational toxicology prediction) are falling on curves similar to Moore's law. They are becoming cheaper rapidly and will continue to do so.

The components that depend on physical infrastructure (GMP manufacturing, cell culture screening, animal toxicology) are falling more slowly. They require facilities, trained personnel, and regulatory compliance that do not digitize easily. GMP manufacturing is the persistent bottleneck, both in cost and in timeline. Wait times for GMP-grade oligonucleotide production at specialized CDMOs can extend to months.

The components that depend on regulatory processes (IND preparation, FDA review) are being actively streamlined. The FDA's guidance on individualized ASO therapies, formalized in 2024, introduced flexible, proportionate oversight that scales regulatory requirements to the risk profile of the specific therapy and the precedent established by prior therapies in the same chemistry class. Each approved ASO reduces the regulatory burden for the next one in the same class.

The net trajectory: the $2 million milasen program will look expensive relative to the individualized ASO programs of 2030. The computational steps will cost less. The GMP manufacturing will become more efficient as CDMOs build dedicated capacity for short-run oligonucleotide production. The regulatory pathway will be more established, requiring less bespoke preparation. The cost curve is pointing toward $500,000 or less per program within the next decade, and possibly lower as the manufacturing and regulatory infrastructure matures.

The Comparison That Matters

The relevant comparison for individualized therapy cost is not the price of a mass-market drug. It is the lifetime cost of managing the disease without a curative therapy.

A child with a severe metabolic disease who requires lifelong enzyme replacement therapy at $300,000 per year accumulates $15 million in drug costs by age 50, plus the costs of biweekly infusions, hospitalizations, specialist visits, respiratory support, mobility equipment, and lost parental productivity. A child with a severe neurological disease who requires 24-hour care accumulates millions in lifetime medical and support costs, plus the economic impact on the family.

A one-time individualized therapy at $1 to $3 million, if it addresses the underlying genetic cause and eliminates or substantially reduces the downstream medical burden, is the least expensive option by any actuarial measure. The challenge is not the total cost. The challenge is the payment structure: health insurance systems are designed for chronic monthly expenditures, not one-time curative payments. A $300,000 annual drug bill is manageable within standard insurance frameworks. A $2 million one-time payment strains them.

This is a financing problem. Outcomes-based contracts, annuity payment models, and reinsurance mechanisms are being developed to address it. The economics favor the cure. The payment infrastructure has not caught up.

The Gene Therapy Cost Comparison

Gene therapy, the other curative approach for genetic disease, has a different cost structure. AAV vector manufacturing is more expensive than oligonucleotide synthesis: a clinical-grade batch of AAV vector for a single gene therapy dose can cost $500,000 to $1 million to manufacture. The viral vector must be produced in large quantities, purified to high purity, tested for potency and safety, and stored under controlled conditions.

Gene therapy development programs have historically cost $50 million to $500 million through traditional pharmaceutical pipelines. The parent-driven gene therapy programs now emerging (Trophos, developed by Terry Pirovolakis for his son's condition) are compressing these costs through academic collaboration, public fundraising, and regulatory pathways that did not exist a decade ago. The manufacturing component remains expensive.

The ASO platform has a structural cost advantage for individualized therapy because the molecules are smaller, simpler to synthesize, and producible through established chemistry. Gene therapy has a durability advantage: a gene delivered once may express for life, while an ASO must be readministered on a regular schedule (typically every few months for intrathecal delivery).

The choice between platforms depends on the biology of the specific condition, the accessibility of the target tissue, the durability requirements, and the manufacturing infrastructure available. For many ultra-rare neurological conditions, intrathecal ASOs are the fastest path to treatment. For conditions where permanent gene correction is feasible and the target tissue is accessible to viral vectors, gene therapy may be more efficient over a lifetime despite higher upfront costs.

The Scale Question

The individualized therapy model does not need to treat millions of people to be economically viable. It needs the cost per program to fall below the lifetime cost of disease management for the individual it treats. That threshold has already been crossed for many severe genetic conditions.

The question is throughput: how many individualized programs can the current infrastructure support per year? Milasen was a single program at a single academic center. The n-of-1 ASO programs that have followed (more than a dozen since milasen) are distributed across a small number of academic centers with the required expertise. The PMF regulatory framework enables master protocols that can accommodate multiple individualized therapies under a single application, reducing the per-program regulatory burden.

The manufacturing bottleneck is the binding constraint. If GMP oligonucleotide production capacity grows and costs decline, and if the regulatory framework continues to streamline, the number of individualized ASO programs that can be developed per year rises from single digits to dozens, then hundreds. At hundreds of programs per year, the infrastructure becomes self-sustaining: each program generates safety and efficacy data that reduces the burden for the next, the manufacturing capacity scales with demand, and the regulatory precedent accumulates.

The economics of one are already viable. The economics of a hundred require the infrastructure to scale. The economics of a thousand require the data from the first hundred to compound. Each treated person makes the next treatment faster, cheaper, and more certain. The drug is made for one. The infrastructure serves all of them.